Matches in SemOpenAlex for { <https://semopenalex.org/work/W4244872894> ?p ?o ?g. }
- W4244872894 endingPage "589" @default.
- W4244872894 startingPage "578" @default.
- W4244872894 abstract "The relationships between dihydrofolate reductase (DHFR) levels or methotrexate membrane transport and acute lymphoblastic leukemia (ALL) immunophenotype were evaluated on 51 T-cell and 44 B-precursor ALL specimens from 90 pediatric ALL patients at diagnosis and relapse, using a fluorescent methotrexate analog (PT430) and flow cytometry assay (Matherly et al, Blood 85:500, 1995). For T-cell ALL, 35 of 45 (78%) of newly diagnosed patients' specimens exhibited elevated DHFR relative to DHFR levels in ALL blasts from methotrexate-responsive patients. For 30 of 45 diagnostic T-ALL specimens, DHFR expression was heterogeneous, with up to 3 separate subpopulations covering a 44-fold range; the DHFR-overproducing fractions comprised 10% to 88% of the total blasts. Elevated DHFR was less common in B-precursor ALL at diagnosis, being detected in only 17 of 36 specimens (47%); 11 of these samples exhibited DHFR heterogeneity. Median maximal DHFR levels were fourfold higher in T-cell than B-precursor ALL at diagnosis. Within a particular phenotypic group, there were no correlations between DHFR levels and patient prognostic features, including age, sex, chromosomal abnormalities, white blood cell counts (WBCs), and percentage of S-phase. However, for B-precursor ALL, there was a notably higher fraction of African-American than white patients with elevated DHFR. For patients (both phenotypes) with low WBCs (<50,000/μL), event-free survival times were significantly shorter for those expressing DHFR above a threshold level than for patients expressing DHFR below this level (P < .016); this relationship was not seen for patients with high WBCs (<50,000/μL). Elevated DHFR was detected in 11 of 14 relapse specimens (5 of 6 T-cell and 6 of 8 B-precursor). Two of five paired relapse specimens (both T-cell) from patients treated with methotrexate exhibited increased DHFR levels over those at diagnosis (2.5- to 5-fold); the fraction of DHFR-overproducing blasts was also increased in 4 of 5 paired relapse specimens (2 B-precursor and 2 T-cell). In contrast to the variations in DHFR, highly impaired methotrexate transport was detected in only 6 of 95 ALL specimens, including both diagnosis and relapse. There was no correlation between phenotype and impaired transport. These data provide further rationale for the use of mechanistically based prognostic factors to complement known biologic or disease-based prognostic indicators in the design of ALL therapy including methotrexate, particularly with patients presenting with low WBCs. The finding of a markedly increased frequency of DHFR overexpression in T-cell over B-precursor ALL suggests that this difference is associated with the poorer prognosis of patients with T-cell ALL treated with standard-dose antimetabolite therapy and implies that higher-dose methotrexate (≥1 g/m2) during consolidation therapy may be useful in the treatment of this disease." @default.
- W4244872894 created "2022-05-12" @default.
- W4244872894 creator A5007677433 @default.
- W4244872894 creator A5008374158 @default.
- W4244872894 creator A5017584174 @default.
- W4244872894 creator A5024263853 @default.
- W4244872894 creator A5036295405 @default.
- W4244872894 creator A5039683293 @default.
- W4244872894 creator A5043172125 @default.
- W4244872894 creator A5062366315 @default.
- W4244872894 creator A5063853755 @default.
- W4244872894 creator A5072801871 @default.
- W4244872894 creator A5091780832 @default.
- W4244872894 date "1997-07-15" @default.
- W4244872894 modified "2023-10-01" @default.
- W4244872894 title "Increased Frequency of Expression of Elevated Dihydrofolate Reductase in T-Cell Versus B-Precursor Acute Lymphoblastic Leukemia in Children" @default.
- W4244872894 cites W1519925643 @default.
- W4244872894 cites W1540897124 @default.
- W4244872894 cites W1597766366 @default.
- W4244872894 cites W1632815792 @default.
- W4244872894 cites W1804726264 @default.
- W4244872894 cites W1975273638 @default.
- W4244872894 cites W1982900493 @default.
- W4244872894 cites W1984522634 @default.
- W4244872894 cites W1989760732 @default.
- W4244872894 cites W200461798 @default.
- W4244872894 cites W2018315074 @default.
- W4244872894 cites W2053504819 @default.
- W4244872894 cites W2075938749 @default.
- W4244872894 cites W2080070978 @default.
- W4244872894 cites W2083020021 @default.
- W4244872894 cites W2093958150 @default.
- W4244872894 cites W2095969092 @default.
- W4244872894 cites W2119685895 @default.
- W4244872894 cites W2134190122 @default.
- W4244872894 cites W2258528303 @default.
- W4244872894 cites W2273677386 @default.
- W4244872894 cites W2278728288 @default.
- W4244872894 cites W2288197674 @default.
- W4244872894 cites W2328583154 @default.
- W4244872894 cites W2343030119 @default.
- W4244872894 cites W284120598 @default.
- W4244872894 cites W307794556 @default.
- W4244872894 cites W4229695692 @default.
- W4244872894 cites W4235653685 @default.
- W4244872894 cites W4237050388 @default.
- W4244872894 cites W4237876736 @default.
- W4244872894 cites W4242509562 @default.
- W4244872894 cites W4246131883 @default.
- W4244872894 cites W4246386811 @default.
- W4244872894 cites W4247685543 @default.
- W4244872894 doi "https://doi.org/10.1182/blood.v90.2.578.578_578_589" @default.
- W4244872894 hasPublicationYear "1997" @default.
- W4244872894 type Work @default.
- W4244872894 citedByCount "1" @default.
- W4244872894 crossrefType "journal-article" @default.
- W4244872894 hasAuthorship W4244872894A5007677433 @default.
- W4244872894 hasAuthorship W4244872894A5008374158 @default.
- W4244872894 hasAuthorship W4244872894A5017584174 @default.
- W4244872894 hasAuthorship W4244872894A5024263853 @default.
- W4244872894 hasAuthorship W4244872894A5036295405 @default.
- W4244872894 hasAuthorship W4244872894A5039683293 @default.
- W4244872894 hasAuthorship W4244872894A5043172125 @default.
- W4244872894 hasAuthorship W4244872894A5062366315 @default.
- W4244872894 hasAuthorship W4244872894A5063853755 @default.
- W4244872894 hasAuthorship W4244872894A5072801871 @default.
- W4244872894 hasAuthorship W4244872894A5091780832 @default.
- W4244872894 hasBestOaLocation W42448728941 @default.
- W4244872894 hasConcept C153911025 @default.
- W4244872894 hasConcept C196166836 @default.
- W4244872894 hasConcept C203014093 @default.
- W4244872894 hasConcept C2778397455 @default.
- W4244872894 hasConcept C2778461978 @default.
- W4244872894 hasConcept C2778488018 @default.
- W4244872894 hasConcept C2781059491 @default.
- W4244872894 hasConcept C2781107101 @default.
- W4244872894 hasConcept C2781320022 @default.
- W4244872894 hasConcept C2781382166 @default.
- W4244872894 hasConcept C2909962599 @default.
- W4244872894 hasConcept C553184892 @default.
- W4244872894 hasConcept C86803240 @default.
- W4244872894 hasConceptScore W4244872894C153911025 @default.
- W4244872894 hasConceptScore W4244872894C196166836 @default.
- W4244872894 hasConceptScore W4244872894C203014093 @default.
- W4244872894 hasConceptScore W4244872894C2778397455 @default.
- W4244872894 hasConceptScore W4244872894C2778461978 @default.
- W4244872894 hasConceptScore W4244872894C2778488018 @default.
- W4244872894 hasConceptScore W4244872894C2781059491 @default.
- W4244872894 hasConceptScore W4244872894C2781107101 @default.
- W4244872894 hasConceptScore W4244872894C2781320022 @default.
- W4244872894 hasConceptScore W4244872894C2781382166 @default.
- W4244872894 hasConceptScore W4244872894C2909962599 @default.
- W4244872894 hasConceptScore W4244872894C553184892 @default.
- W4244872894 hasConceptScore W4244872894C86803240 @default.
- W4244872894 hasIssue "2" @default.
- W4244872894 hasLocation W42448728941 @default.
- W4244872894 hasOpenAccess W4244872894 @default.
- W4244872894 hasPrimaryLocation W42448728941 @default.